Jove
Visualize
Contact Us

Related Experiment Videos

Hyperacute stroke therapy with tissue plasminogen activator

M J Alberts1

  • 1Division of Neurology, Duke University Medical Center, Durham, North Carolina 27710, USA.

The American Journal of Cardiology
|August 28, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prior anti-thrombotic drugs and stroke mortality.

Heart (British Cardiac Society)·2012
Same author

Secondary preventive medication persistence and adherence 1 year after stroke.

Neurology·2011
Same author

Worse blood pressure control in patients with cerebrovascular or peripheral arterial disease compared with coronary artery disease.

Journal of internal medicine·2010
Same author

Isolation of a cytochrome oxidase gene overexpressed in Alzheimer's disease brain.

Molecular and cellular neurosciences·2009
Same author

High cardiovascular event rates in patients with asymptomatic carotid stenosis: the REACH Registry.

European journal of neurology·2009
Same author

Current strategies for ischemic stroke prevention: role of multimodal combination therapies.

Journal of neurology·2007
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

New stroke therapies, including tissue plasminogen activator (t-PA), show promise in reversing acute stroke effects. While t-PA improves outcomes, ongoing research explores expanded use and combination therapies for better stroke treatment.

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Acute stroke treatment has advanced significantly, with thrombolytic therapy being a key focus for the past seven years.
  • Tissue plasminogen activator (t-PA) gained FDA approval in 1996 for ischemic stroke within 3 hours of onset.
  • t-PA treatment demonstrates significant improvements in neurological outcomes and functional recovery for stroke patients.

Purpose of the Study:

  • To review progress in acute stroke therapies, focusing on thrombolytic agents.
  • To evaluate the benefits and risks associated with t-PA therapy.
  • To explore emerging research directions, including extended treatment windows, alternative agents, and combination therapies.

Main Methods:

  • Review of existing literature on thrombolytic therapies for acute ischemic stroke.

Related Experiment Videos

  • Analysis of clinical trial data regarding t-PA efficacy and safety, including rates of intracerebral hemorrhage (ICH).
  • Discussion of ongoing studies investigating extended t-PA administration, intra-arterial pro-urokinase, and advanced imaging techniques like magnetic resonance spectroscopy.

    • Main Results:

    • Tissue plasminogen activator (t-PA) significantly improves functional outcomes, with 11-13 additional patients per 100 achieving normal or near-normal status at 3 months.
    • t-PA therapy is associated with a 6% rate of symptomatic intracerebral hemorrhage (ICH) and a 3% rate of fatal ICH.
    • Research is exploring the safety and efficacy of t-PA within 5 hours of stroke onset and evaluating other thrombolytic agents.

    Conclusions:

    • The field is moving towards proactive stroke interventions, aiming to reverse acute symptoms and improve functional outcomes.
    • Combination therapies, involving neuroprotectants and thrombolytics, are under investigation for enhanced treatment efficacy.
    • Future stroke management may involve personalized treatment strategies based on patient-specific factors and advanced diagnostic tools.